Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Combined ARV, Antibiotic Treatment Could Reduce HIV Mortality Among Patients in Resource-Limited Settings, Study Finds

March 30, 2010

Simultaneously treating patients living with HIV/AIDS with antiretrovirals (ARVs) and an inexpensive antibiotic known as co-trimoxazole can reduce HIV mortality by 50 percent in the first 18 months of treatment, according to a Lancet study published Monday, VOA News reports (Nyaira, 3/29). "The observational study analyzed 3,179 Ugandan and Zimbabwean participants from the Development of Anti-Retroviral Therapy in Africa (DART) trial, conducted by the MRC in Uganda and Zimbabwe, for almost five years," according to IRIN/PlusNews. Though the WHO recommends "co-trimoxazole prophylaxis for all HIV-infected patients with a CD4 count below 350 ... the DART study found that the use of the antibiotic was inconsistent in Uganda and Zimbabwe," IRIN/PlusNews writes (3/29).

Back to other news for March 2010


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More Research on HIV Treatment in the Developing World
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement